HSOA Stock Chart & Stats
€97.00
-€0.50(-0.51%)
At close: 4:00 PM EDT
€97.00
-€0.50(-0.51%)
Day’s Range― - ―
52-Week Range€78.00 - €110.00
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€10.17B
Enterprise Value€13.63K
Total Cash (Recent Filing)€107.70M
Total Debt (Recent Filing)€2.84B
Price to Earnings (P/E)19.4
Beta0.37
Next Earnings
Oct 28, 2026EPS Estimate
1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.22
Shares Outstanding98,653,380
10 Day Avg. Volume5
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)4.37
Price to Sales (P/S)1.80
P/FCF Ratio24.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€126.21Price Target Upside30.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.28
Revenue Forecast (FY)€5.59B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Earnings GrowthStrong volume, pricing and earnings growth, alongside raised full-year guidance, indicate durable operating momentum. Continued expansion in patient activity and revenue per discharge can support growth over the next several quarters.
Capacity Expansion And De Novo EconomicsA sizeable development pipeline provides a structural avenue for increasing post-acute capacity and market reach. De novo hospitals reportedly achieve positive four-wall EBITDA around month six and over 70% occupancy by month ten.
Workforce Retention And Clinical QualityLower clinician turnover supports staffing stability, service quality and reduced reliance on premium labor. Strong discharge outcomes can reinforce referral relationships and help the company manage growing demand for complex rehabilitation.
Bears Say
Medicare Advantage Denial FrictionPersistent Medicare Advantage denials can delay admissions, increase administrative workload and create reimbursement uncertainty. Even successful appeals may require additional resources, limiting conversion of demand into timely, profitable care.
Labor And Ramp-Up Cost PressureWage inflation and elevated costs for newly opened facilities can pressure margins while the expansion program matures. These expenses may remain relevant across several quarters before labor efficiencies and occupancy gains fully offset them.
High Capital Intensity And Debt ExposureAccelerated hospital development requires substantial capital and limits near-term free-cash-flow flexibility. Meaningful leverage adds financial obligations, making returns more sensitive to occupancy execution, reimbursement changes and construction or operating costs.
Encompass Health News
HSOA FAQ
What was Encompass Health’s price range in the past 12 months?
Encompass Health lowest stock price was €78.00 and its highest was €110.00 in the past 12 months.
What is Encompass Health’s market cap?
Encompass Health’s market cap is €10.17B.
When is Encompass Health’s upcoming earnings report date?
Encompass Health’s upcoming earnings report date is Oct 28, 2026 which is in 62 days.
How were Encompass Health’s earnings last quarter?
Encompass Health released its earnings results on Aug 05, 2026. The company reported €1.341 earnings per share for the quarter, beating the consensus estimate of €1.281 by €0.061.
Is Encompass Health overvalued?
According to Wall Street analysts Encompass Health’s price is currently Undervalued.
Does Encompass Health pay dividends?
Encompass Health does not currently pay dividends.
What is Encompass Health’s EPS estimate?
Encompass Health’s EPS estimate is 1.18.
How many shares outstanding does Encompass Health have?
Encompass Health has 98,653,380 shares outstanding.
What happened to Encompass Health’s price movement after its last earnings report?
Encompass Health reported an EPS of €1.341 in its last earnings report, beating expectations of €1.281. Following the earnings report the stock price went up 2.083%.
Which hedge fund is a major shareholder of Encompass Health?
Currently, no hedge funds are holding shares in DE:HSOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Encompass Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€126.21 (30.11% Upside)
€126.21 (30.11% Upside)
Blogger Sentiment
Bullish
DE:HSOA Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €21.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.52%
12-Months-Change
Fundamentals
Return on Equity
0.64%
Trailing 12-Months
Asset Growth
9.90%
Trailing 12-Months
Company Description
Encompass Health
Encompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients' homes. The company's operations are divided into two primary divisions: Inpatient Rehabilitation, and Home Health and Hospice. Its Inpatient Rehabilitation division specializes in providing focused recovery treatment, available on an inpatient or outpatient basis. This care is designed for individuals recuperating from significant health challenges such as strokes, neurological disorders, cardiac and pulmonary issues, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment primarily serves the Southeast and Texas regions. Within this segment, home health services encompass a variety of Medicare-certified care options for adult patients, including skilled nursing, medical social work, home health aide assistance, and various therapies like physical, occupational, and speech therapy. Hospice services, on the other hand, provide in-home comfort and support for terminally ill patients and their families. As of June 1, 2022, Encompass Health maintained a substantial network, managing 149 hospitals, 252 home health locations, and 99 hospice locations spread across 42 U.S. states and Puerto Rico. The company, which established its roots in 1983 and is headquartered in Birmingham, Alabama, was formerly known as HealthSouth Corporation until its name change to Encompass Health Corporation in January 2018.
HSOA Company Deck
HSOA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial story: strong top-line and EPS growth, raised 2026 guidance, improving occupancy and de novo ramp economics, meaningful workforce improvements driving retention and quality, successful capital-return actions (dividend increase and repurchase authorization), and a favorable CMS pricing rule offsetting some pressures. Key challenges include a retroactive Florida net provider tax adjustment (~$11M adverse impact), higher SWB and preopening costs, persistent Medicare Advantage denial friction, and increased CapEx intensity. Overall, the positives (revenue/EBITDA/EPS growth, guidance raise, quality metrics, pipeline, and successful workforce initiatives) materially outweigh the manageable negatives described.View all DE:HSOA earnings summariesHSOA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€126.21
▲(30.11% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
DaVita
―
Fresenius Medical Care
―
Tenet Healthcare
―
The Ensign Group
―
Universal Health
―










